Clinical Trial

Immune Tolerance Induction After Liver Transplantation

Study acronym: iTILT
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-03; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2026-03-10
Trial Details
NCT Number NCT07269041
Lead Sponsor University of California, Los Angeles
Conditions Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders +1 more
Enrollment 12 participants
Start Date 2026-02-20
Primary Completion 2029-01 (estimated)
Study Completion 2033-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12